Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain forms of non‑small cell lung cancer. The drug works by blocking multiple growth factor receptors that drive fibroblast activity and abnormal tissue remodeling, thereby slowing disease progression.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is used in fibrotic lung diseases and selected oncology indications, targeting pathways that promote fibroblast proliferation and tumor growth.

Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and stabilizes respiratory symptoms. Non‑small cell lung cancer: used in combination therapy to inhibit tumor angiogenesis and growth.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often manageable with diet and antidiarrheal agents. - Nausea: feeling of sickness, may be reduced with food intake. - Vomiting: occasional episodes, usually mild. - Decreased appetite: reduced desire to eat, can lead to weight loss. - Abdominal pain: mild to moderate discomfort. - Elevated liver enzymes: increased ALT/AST on laboratory testing.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Major bleeding: gastrointestinal or other hemorrhage, especially with anticoagulants. - Cardiovascular events: myocardial infarction or stroke in at‑risk patients. - Gastrointestinal perforation: rare but serious intestinal injury. - Severe infections: opportunistic infections in immunocompromised individuals.

Before initiating Nintedanib, several safety considerations should be reviewed.

Liver function monitoring: perform baseline and periodic liver enzyme tests. Cardiovascular assessment: evaluate for history of ischemic heart disease before initiating. Bleeding risk: avoid concomitant use with strong anticoagulants unless necessary. Gastrointestinal tolerance: manage diarrhea with diet and antidiarrheal agents. Pregnancy and lactation: safety not established; avoid use in pregnant or breastfeeding women. Store at below 25°C: keep in the original packaging, protect from moisture and light.

Nintedanib can interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Potent P‑gp inhibitors (e.g., verapamil): can raise plasma levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise concentrations. - Antacids or proton‑pump inhibitors: may affect absorption; separate dosing by at least 2 hours. - Calcium channel blockers (e.g., amlodipine): monitor for additive vascular effects.